stutes
12 Sep 2018
Stroke trial in USA In expanding its research portfolio have Rene failed to resource its USA stroke trial properly so as to hit trial deadlines/publish data? If you look at the history of the stroke treatment trial it looks to me as suffered a few delays. Time to put a closer in to hit deadlines
loper
04 Sep 2018
Share price I must have missed something. Partnering deal ? Who with ?
JensonBensonJohnson
04 Sep 2018
Share price Well they are in the middle of a due diligence period for a partnering deal. That’s a game-changing situation for RENE. If it goes ahead hopefully they won’t have to tap shareholders for a long time, if ever. Expecting RNS update next week before the AGM (Wednesday 12th September)
stutes
04 Sep 2018
Share price Low share price and almost 10 month + wait period for stroke phase 3 trial to commence shows to me the company needs to change fast if it is to tap shareholders in the future. The clock is ticking on Rene
charlton_vach
03 Sep 2018
Prevalence of Retinitis Pigmentosa in China A nice number of prospective punters JBJ. I’m just back in for a couple of grand, this share price seems too low to be true…mind you, I’ve said that a few times over the years
ian_vacher
03 Sep 2018
Prevalence of Retinitis Pigmentosa in China A nice number of prospective punters JBJ. I’m just back in for a couple of grand, this share price seems too low to be true…mind you, I’ve said that a few times over the years
JensonBensonJohnson
31 Aug 2018
Prevalence of Retinitis Pigmentosa in China The proposed licensing deal deliberately excludes China. Prevalence of RT in the West seems to be around 1/4000 people so I wondered what the statistics were for China. This article seems to put the figure at around 1/1000 in China: ncbi.nlm.nih.gov Prevalence of retinitis pigmentosa in urban and rural adult Chinese: The Beijing Eye Study. L Xu, L Hu, K Ma, J Li and JB Jonas, European journal of ophthalmology, Nov-Dec 2006 To determine the prevalence of retinitis pigmentosa in the elderly Chinese population.The Beijing Eye Study is a population-based, cross-sectional cohort study and included 4439 subjects out of 5324 subjects invited to participate (response rate 83.4%) with an age of 40+ years. Readable fundus photographs were available for 4027 (90.7%) subjects. Diagnostic criteria for retinitis pigmentosa were visual field defects on frequency doubling perimetry, typical ophthalmoscopic abnormalities such as retinal pigment deposits, retinal arteriole attenuation, and pigment epithelial atrophy, and no other reason for perimetric defects and fundus abnormalities.Retinitis pigmentosa was diagnosed in four subjects (all men). Its prevalence was 0.099+/-3.15% (95% CI: 0.00, 0.2).Retinitis pigmentosa with typical fundus appearance and functional loss may be present in about 1 out of 1000 elderly Chinese in Northern China. Calculated for the whole population in China, the figure would be 1.3 million patients with retinitis pigmentosa. … so 4 times as prevalent and seeing as 1/5 people in the world are Chinese that makes its market almost as big as the rest put together, so I can see why they want to license it there separately.
fhjhiscock
29 Aug 2018
Any Guesses who US Partner might be? That would be a result
JensonBensonJohnson
29 Aug 2018
Any Guesses who US Partner might be? I wonder if it could be SanBio themselves? Combine our technologies and corner the market.
JensonBensonJohnson
28 Aug 2018
Pisces III I’ve read back through historic threads, and I can see you posted that video back in April, Mol.
JensonBensonJohnson
28 Aug 2018
Pisces III Hi Freddie, Mol, I’ve not read anything about the MHRA manufacturing. All their focus now is on trials in the US, though, isn’t it? How does MHRA manufacturing licence fit in to that? Have you watched this? It’s a few months old, but just in case it passed you by: youtu.be/0M5hWS-tE3k The whole thing is well worth a watch, 17 1/2 minutes. But if you’re pressed for time watch from 13 minutes to 15 minutes to see what he says about a competitor, “San Bio†and the wild disparity between their market caps.
mol42
27 Aug 2018
Pisces III Yes MHRA manufacturing licence mol
fhjhiscock
26 Aug 2018
Pisces III Hi Jensen …My guess is mol was referring to the new manufacturing facility …
JensonBensonJohnson
26 Aug 2018
Pisces III Mol, when you talk about a delay with the licence, what licence are you referring to?
fhjhiscock
26 Aug 2018
Pisces III …So sad john McCain has passed away as yet another victim of glioblastoma…On that same cancer subject, I am awaiting news from Reneuron regarding their exosome delivery mechanism directed at taking the treatment directly to the tumour. Rene isn’t it time for an update regarding your JV initiative…
